Piperidine or piperazine linked imidazole and triazole derivatives and methods of use

Patent metadata

Field	Value
Publication number	US-10745377-B2
Application number	US-201415036268-A
Country	US
Kind code	B2
Filing date	Nov 7, 2014
Priority date	Nov 12, 2013
Publication date	Aug 18, 2020
Grant date	Aug 18, 2020

Abstract

The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

First claim

What is claimed is:

1. A compound having the formula (I):

or a pharmaceutically acceptable salt thereof,
wherein:
n is 1;
W is —N═ or —CH═;
X is —N(R 3 )—;
R 1 is selected from —(C 1 -C 6 alkylene)-aryl, —(C 1 -C 6 alkylene)-(5 or 6-membered heteroaryl), —(C 1 -C 6 alkylene)-O-aryl, —(C 1 -C 6 alkylene)-O-(5 or 6-membered heteroaryl) and C 3 -C 6 cycloalkyl, wherein any aryl, heteroaryl or C 3 -C 6 cycloalkyl group can be optionally substituted with up to four R 9 groups, which can be the same or different, and wherein said C 3 -C 6 cycloalkyl group can be fused to a benzene ring and said fused benzene ring can be optionally substituted with up to four R 9 groups, which can be the same or different;
one occurrence of R 2 is H and the other occurrence of R 2 is C 1 -C 6 alkyl;
R 3 is selected from Y, —O—Y, —C(O)—Y, —(C 1 -C 6 alkylene)-Y, —(C 1 -C 6 alkylene)-C(O)—Y, —(C 1 -C 6 alkylene)-C(O)—O—Y and —(C 1 -C 6 alkylene)-O—Y, wherein each Y is independently selected from:
(1) C 1 -C 4 alkyl,
(2) C 1 -C 4 haloalkyl,
(3) C 1 -C 4 hydroxyalkyl,
(4) C 3 -C 6 cyclohaloalkyl,
(5) C 3 -C 6 cycloalkyl,
(6) phenyl, wherein said phenyl group can be optionally substituted with up to four R 7 groups,
(7) 5 or 6-membered heteroaryl, wherein said 5 or 6-membered heteroaryl group can be optionally substituted with up to four R 7 groups, and
(8) 5 or 6-membered monocyclic heterocycloalkyl or 9 or 10-membered bicyclic heterocycloalkyl, wherein said 5 or 6-membered monocyclic heterocycloalkyl group can optionally form a spirocycle with a C 3 -C 6 cycloalkyl group or another 5 or 6-membered monocyclic heterocycloalkyl group, and wherein said 5 or 6-membered monocyclic heterocycloalkyl group and said 9 or 10-membered bicyclic heterocycloalkyl group can be optionally substituted on one or more ring carbon atoms with up to four R 7 groups, which can be the same or different, and wherein a ring carbon atom of a 5 or 6-membered monocyclic heterocycloalkyl group may be functionalized as a carbonyl group;
R 5 is selected from H, C 1 -C 6 alkyl, phenyl, —C(O)N(R 8 ) 2 and —C(O)—Z, wherein Z is selected from piperidinyl, piperazinyl and morhoplinyl and wherein said Z is optionally substituted with 1 to 3 halo groups, and phenyl is optionally substituted with —N(R 8 ) 2 ,
R 6 is H;
each occurrence of R 7 and each occurrence of R 9 are is independently selected from C 1 -C 6 alkyl, phenyl, benzyl, 5 or 6-membered heteroaryl, —CH 2 -(5 or 6-membered heteroaryl), 5 or 6-membered heterocycloalkyl, —CH 2 -(5 or 6-membered heterocycloalkyl), C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, halo, —CN, —N(R 8 ) 2 , —(C 1 -C 6 alkylene)-N(R 8 ) 2 , —OR 8 , —C(O)OR 8 , —SR 8 , —S(O) 2 R 8 , —C(O)N(R 8 ) 2 , —(C 1 -C 6 alkylene)-C(O)OR 8 , —(C 1 -C 6 alkylene)-SR 8 , —(C 1 -C 6 alkylene)-S(O) 2 R 8 and (C 1 -C 6 alkylene)-C(O)N(R 8 ) 2 , wherein said phenyl, 5 or 6-membered heteroaryl and 5 or 6-membered heterocycloalkyl groups can be optionally substituted with one to three groups selected from C 1 -C 6 alkyl, halo, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, halo, —CN, —N(R 8 ) 2 and —OR 8 ; and
each occurrence of R 8 is independently H, C 1 -C 6 alkyl or benzyl optionally substituted with one or two methoxy groups.

2. The compound of claim 1 , having the formula (Ib):

or a pharmaceutically acceptable salt thereof, wherein R 9 is present and is F or —CN.

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 3 is thiazolyl substituted with —(C 1 -C 6 alkylene)-S(O) 2 R 8 , R 5 is H, and R 6 is H.

4. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 3 is phenyl, R 5 is —C(O)—Z, wherein Z is selected from piperidinyl, piperazinyl and morhoplinyl and wherein said Z is optionally substituted with 1 to 3 halo groups, and R 6 is H.

5. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 3 is —C(O)—Y, Y is selected from (1) cyclobutyl, (2) phenyl, (3) pyridinyl, and (4) tetrahydro-2H-pyran-4-yl; R 5 is selected from H, C 1 -C 4 alkyl and phenyl; and R 6 is H.

6. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein
R 3 is selected from C 1 -C 6 hydroxyalkyl, —(C 1 -C 6 alkylene)-C(O)—Y, —(C 1 -C 6 alkylene)-C(O)—O—Y and —(C 1 -C 6 alkylene)-O—Y;
Y is C 1 -C 4 alkyl;
R 5 is H; and
R 6 is H.

7. A compound selected from the following:
(R)-2-(4-((1-(1-(4-fluorophenyl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
(R)-4-(1-(5-((4-(benzo[d]oxazol-2-yl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
4-(1-(5-((4-(benzo[d]oxazol-2-yl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)cyclopropyl)benzonitrile;
2-(4-((1-(2-isopropoxyethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
2-(4-((1-(3-methylbutan-2-yl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
(R)-4-(1-(5-((4-(7-fluorobenzo[d]oxazol-2-yl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
(R)-4-(1-(5-((4-(7-methylbenzo[d]oxazol-2-yl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
(R)-4-(1-(5-((4-(6-fluorobenzo[d]oxazol-2-yl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
(R)-4-(1-(5-((4-(6,7-difluorobenzo[d]oxazol-2-yl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
2-(4-((1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
2-(4-((1-(2-(pyridin-2-yl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
2-(4-((1-(1-(4-(methylsulfonyl)phenyl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
6,7-difluoro-2-(4-((1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
2-(4-((1-(3,3,3-trifluoro-2-methylpropyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
2-(4-((1-(4-fluorophenethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole;
(R)-4-(1-(5-((4-(6-methoxybenzo[d]thiazol-2-yl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
(R)-4-(1-(5-((4-(1H-benzo[d]imidazol-2-yl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
(R)-5-(ethylsulfonyl)-2-(4-((1-(1-(4-fluorophenyl)propan-2-yl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)thiazole;
(R)-5-(2-(ethylsulfonyl)ethyl)-2-(4-((1-(1-(4-fluorophenyl)propan-2-yl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)thiazole;
(R)-2-(4-((1-(1-(4-chlorophenyl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)-5-(2-(ethylsulfonyl)ethyl)thiazole;
(R)-2-(4-((1-(1-(4-fluorophenyl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)-5-(2-(ethylsulfonyl)ethyl)thiazole;
N-(tert-butyl)-4-((1-((R)-1-(4-cyanophenyl)ethyl)-1H-imidazol-5-yl)methyl)-1-phenylpiperazine-2-carboxamide;
4-((1R)-1-(5-((4-phenyl-3-(piperidine-1-carbonyl)piperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
4-((1R)-1-(5-((3-(morpholine-4-carbonyl)-4-phenylpiperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
4-((1R)-1-(5-((3-(4,4-difluoropiperidine-1-carbonyl)-4-phenylpiperazin-1-yl)methyl)-1H-imidazol-1-yl)ethyl)benzonitrile;
((S)-4-((1-((R)-1-(4-fluorophenyl)ethyl)-1H-imidazol-5-yl)methyl)-1-phenylpiperazin-2-yl)(piperidin-1-yl)methanone;
(4-((1-((R)-1-(4-fluorophenyl)ethyl)-1H-imidazol-5-yl)methyl)-2-phenylpiperazin-1-yl)(5-methylisoxazol-3-yl)methanone;
(4-((1-((R)-1-(4-fluorophenyl)ethyl)-1H-imidazol-5-yl)methyl)-2-phenylpiperazin-1-yl)(phenyl)methanone;
1-(4-((1-((R)-1-(4-fluorophenyl)ethyl)-1H-imidazol-5-yl)methyl)-2-phenylpiperazin-1-yl)ethanone;
(4-((1-((R)-1-(4-fluorophenyl)ethyl)-1H-

Assignees

• Merck Sharp & Dohme
• Coburn Craig A
• Maletic Milana M
• Luo Yunfu
• Qi Zhiqi
• Yu Tingting
• Soll Richard

Inventors

• Coburn Craig A
• Maletic Milana M
• Luo Yunfu
• Qi Zhiqi
• Yu Tingting
• Soll Richard

Classifications

• C07D213/14

  Preparation from compounds containing heterocyclic oxygen · CPC title

• C07D409/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C07D233/61

  with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms · CPC title

• A61K31/496

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• C07D249/08

  1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles · CPC title